公开(公告)号：US20110224414A1

公开(公告)日：2011-09-15

申请号：US13130130

申请日：2009-11-23

Applicant: Shuguang Wang ,  Jin Zhong ,  Deyun Kong ,  Jue Hu ,  Bo Li ,  Wen Gao ,  Chunyan Gai ,  Changiong Zhuang ,  Haitao Mao

Inventor： Shuguang Wang ,  Jin Zhong ,  Deyun Kong ,  Jue Hu ,  Bo Li ,  Wen Gao ,  Chunyan Gai ,  Changiong Zhuang ,  Haitao Mao

IPC: C07H15/24 ,  C07C309/44 ,  C07C49/675

CPC classification number: A61K31/122 ,  A61K31/185 ,  A61K31/192 ,  A61K31/7004 ,  A61K31/704 ,  A61K36/482 ,  A61K36/708 ,  A61K36/74

Abstract: Use of 9,10-anthraquinone compounds of formula (I) or pharmaceutical salts thereof or plant extracts containing said compounds in the preparation of anti-HCV medicaments is disclosed, in which Y1 are Y2 are independently hydrogen, hydroxyl or groups of formula (II); and R1, R2, R3, R4, R5 and R6 are independently hydrogen, hydroxyl, carboxyl, cyano group, nitro group, groups of formula (III) or groups selected from those substituted or unsubstituted groups: amino, C1-C6 aliphatic hydrocarbon, C3-C7 cyclic aliphatic hydrocarbon, C1-C6 alkoxy, C2-C7 carbalkoxy, C1-C4 acyloxy, C6-C20 aryl, or 5 to 7 members heterocyclic or benzoheterocyclic thereof; or R5 and R6 form the group of formula (IV). The compounds of present invention are cheap, safe and effective, because that they mostly conic from traditional Chinese medicines and have better anti-HCV effects and lighter side effects.

Abstract translation: 公开了在制备抗HCV药物中使用式（I）的9,10-蒽醌化合物或其药用盐或含有所述化合物的植物提取物，其中Y 1为Y 2独立地为氢，羟基或式（II ）; 并且R 1，R 2，R 3，R 4，R 5和R 6独立地是氢，羟基，羧基，氰基，硝基，式（III）的基团或选自那些取代或未取代的基团的基团：氨基，C 1 -C 6脂族烃， C 3 -C 7环脂族烃，C 1 -C 6烷氧基，C 2 -C 7烷酰氧基，C 1 -C 4酰氧基，C 6 -C 20芳基或5至7元杂环或苯并杂环; 或R 5和R 6形成式（IV）的基团。 本发明化合物廉价，安全有效，因为它们大多是中药复方，抗HCV效果更好，副作用更轻。

公开(公告)号：US20100152263A1

公开(公告)日：2010-06-17

申请号：US12710301

申请日：2010-02-22

Applicant: Mehdi PABORJI

Inventor： Mehdi PABORJI

IPC: A61K31/4178 ,  A61P13/10

CPC classification number: A61K31/4178 ,  A61K31/00 ,  A61K31/137 ,  A61K31/216 ,  A61K31/4025 ,  A61K31/4172 ,  A61K31/439 ,  A61K31/46 ,  A61K31/717 ,  A61K33/06 ,  A61K36/482 ,  A61K36/68 ,  A61K36/72 ,  A61K45/06 ,  A61K2300/00

Abstract: Disclosed herein are pharmaceutical compositions comprising oxybutynin or tolterodine, or a free base thereof or a pharmaceutically acceptable salt thereof, and pilocarpine, or a free base thereof or a pharmaceutically acceptable salt thereof. Also disclosed are methods of treating a patient suffering from overactive bladder comprising administering to the patient the above pharmaceutical composition.

Abstract translation: 本文公开了包含奥昔布宁或托特罗定或其游离碱或其药学上可接受的盐，毛果芸香碱或其游离碱或其药学上可接受的盐的药物组合物。 还公开了治疗患有膀胱过度活动症的患者的方法，包括向患者施用上述药物组合物。

公开(公告)号：US07691418B2

公开(公告)日：2010-04-06

申请号：US11663119

申请日：2005-09-16

Applicant: Bart Rossel

Inventor： Bart Rossel

IPC: A61K36/00

CPC classification number: A61K36/73 ,  A61K31/122 ,  A61K31/48 ,  A61K36/185 ,  A61K36/23 ,  A61K36/232 ,  A61K36/258 ,  A61K36/28 ,  A61K36/31 ,  A61K36/38 ,  A61K36/45 ,  A61K36/48 ,  A61K36/482 ,  A61K36/53 ,  A61K36/54 ,  A61K36/58 ,  A61K36/59 ,  A61K36/61 ,  A61K36/70 ,  A61K36/752 ,  A61K36/81 ,  A61K36/87 ,  A61K36/886 ,  A61K36/8962 ,  A61K45/06 ,  A61K2300/00

Abstract: Compounds for inhibiting and/or preventing the formation of a biofilm are disclosed. The compounds are an anthraquinone and/or a naphtoquinone, stereoisomeric forms, racemic mixtures, metabolites, esters or salts thereof, or mixtures thereof, and/or at least one plant extract including the compound or active fraction thereof. Compositions containing the compounds such as oral health products and methods of using the products in a method to prevent or inhibit biofilm formation are also disclosed. Preferred compositions include emodin and/or plant extracts from Rheum sp.

Abstract translation: 公开了用于抑制和/或防止生物膜形成的化合物。 化合物是蒽醌和/或萘醌，立体异构形式，外消旋混合物，代谢物，酯或其盐，或其混合物，和/或至少一种植物提取物，包括其化合物或其活性部分。 还公开了含有化合物的组合物，例如口腔保健产品和在防止或抑制生物膜形成的方法中使用该产品的方法。 优选的组合物包括大黄素和/或大黄素植物提取物。

公开(公告)号：US07678821B2

公开(公告)日：2010-03-16

申请号：US11467760

申请日：2006-08-28

Applicant: Mehdi Paborji

Inventor： Mehdi Paborji

IPC: A61K31/4178 ,  A61K31/137

CPC classification number: A61K31/4178 ,  A61K31/00 ,  A61K31/137 ,  A61K31/216 ,  A61K31/4025 ,  A61K31/4172 ,  A61K31/439 ,  A61K31/46 ,  A61K31/717 ,  A61K33/06 ,  A61K36/482 ,  A61K36/68 ,  A61K36/72 ,  A61K45/06 ,  A61K2300/00

Abstract: Disclosed herein are pharmaceutical compositions comprising combinations of tolterodine, an antimuscarinic agent, and pilocarpine, a compound that causes stimulation of salivary glands. Also disclosed are methods of treating a patient suffering from overactive bladder comprising administering to the patient said pharmaceutical composition.

Abstract translation: 本文公开了包含托特罗定，抗毒蕈碱剂和毛果芸香碱的组合的药物组合物，其是引起刺激唾液腺的化合物。 还公开了治疗患有膀胱过度活动症的患者的方法，包括向患者施用所述药物组合物。

公开(公告)号：US07666894B2

公开(公告)日：2010-02-23

申请号：US12555806

申请日：2009-09-08

Applicant: Mehdi Paborji

Inventor： Mehdi Paborji

IPC: A61K31/4178 ,  A61K31/216

CPC classification number: A61K31/4178 ,  A61K31/00 ,  A61K31/137 ,  A61K31/216 ,  A61K31/4025 ,  A61K31/4172 ,  A61K31/439 ,  A61K31/46 ,  A61K31/717 ,  A61K33/06 ,  A61K36/482 ,  A61K36/68 ,  A61K36/72 ,  A61K45/06 ,  A61K2300/00

Abstract: Disclosed herein are pharmaceutical compositions comprising oxybutynin, or a free base thereof or a pharmaceutically acceptable salt thereof, and pilocarpine, or a free base thereof or a pharmaceutically acceptable salt thereof. Also disclosed are methods of treating a patient suffering from overactive bladder comprising administering to the patient the above pharmaceutical composition.

Abstract translation: 本文公开了包含奥昔布宁或其游离碱或其药学上可接受的盐，毛果芸香碱或其游离碱或其药学上可接受的盐的药物组合物。 还公开了治疗患有膀胱过度活动症的患者的方法，包括向患者施用上述药物组合物。

公开(公告)号：US20090304831A1

公开(公告)日：2009-12-10

申请号：US12477566

申请日：2009-06-03

Applicant: Ken CLEMENT ,  Marvin A. Heuer ,  William Ha ,  Megan Thomas ,  Erin Taraborrelli ,  Krista Rutherford

Inventor： Ken CLEMENT ,  Marvin A. Heuer ,  William Ha ,  Megan Thomas ,  Erin Taraborrelli ,  Krista Rutherford

IPC: A61K36/482 ,  A61K36/72 ,  A61K36/708 ,  A61P1/00

CPC classification number: A61K36/28 ,  A61K36/48 ,  A61K36/482 ,  A61K36/708 ,  A61K36/72 ,  A61K2300/00

Abstract: An improved laxative composition is provided having efficacy with reduced negative side-effects. The laxative composition is also provided with agents that promote healthy intestinal and liver function, reduce carbohydrate absorption and have antioxidant capacity. A method is also provided for reducing the negative side-effects associated with Anthranoid-based laxative compositions. A method is further provided for increasing the efficacy and/or duration of effect of Anthranoid-based laxative compositions.

Abstract translation: 提供改善的泻药组合物具有降低的负面副作用的功效。 泻药组合物还提供促进健康的肠和肝功能，减少碳水化合物吸收并具有抗氧化能力的药剂。 还提供了一种减少与基于蒽醌的轻泻组合物相关的负面副作用的方法。 还提供了一种用于增加基于蒽醌的泻药组合物的效果和/或持续时间的方法。

公开(公告)号：US07611736B2

公开(公告)日：2009-11-03

申请号：US12420602

申请日：2009-04-08

Applicant: Wolfgang Morick ,  Lars-Norbert Prenner ,  Michael Hubbert ,  Kurt Gebhart ,  Wolf Behm

Inventor： Wolfgang Morick ,  Lars-Norbert Prenner ,  Michael Hubbert ,  Kurt Gebhart ,  Wolf Behm

IPC: A61K36/68 ,  A61K36/00

CPC classification number: A61K36/482 ,  A61K31/704 ,  A61K36/68 ,  A61K2300/00

Abstract: The invention relates to a pharmaceutical composition which is suitable in particular for use as purgative (cathartic), where the composition comprises in combination and in each case in pharmaceutically effective amounts (A) senna fruit dry extract and (B) plantago seeds (plantaginis ovatae semen). The composition can advantageously be manufactured by fluidized bed granulation. The composition is in particular free of guar gum, is dust-free, is dispersible in water and has a pleasant taste and can be supplemented straightforwardly with vitamins, minerals, trace elements and the like.

Abstract translation: 本发明涉及一种药物组合物，其特别适合用作泻药（泻药），其中组合物组合包含药学有效量（A）番泻奈果干提取物和（B）车前草种子（plantaginis ovatae 精液）。 组合物可以有利地通过流化床造粒制备。 该组合物特别是没有瓜尔胶，无尘，可分散在水中并具有令人愉悦的味道，并可直接补充维生素，矿物质，微量元素等。

公开(公告)号：US20090186106A1

公开(公告)日：2009-07-23

申请号：US12420602

申请日：2009-04-08

Applicant: Wolfgang Morick ,  Lars-Norbert Prenner ,  Michael Hubbert ,  Kurt N. Gebhart ,  Wolf Behm

Inventor： Wolfgang Morick ,  Lars-Norbert Prenner ,  Michael Hubbert ,  Kurt N. Gebhart ,  Wolf Behm

IPC: A61K36/68 ,  A61P1/10

CPC classification number: A61K36/482 ,  A61K31/704 ,  A61K36/68 ,  A61K2300/00

Abstract: The invention relates to a pharmaceutical composition which is suitable in particular for use as purgative (cathartic), where the composition comprises in combination and in each case in pharmaceutically effective amounts (A) senna fruit dry extract and (B) plantago seeds (plantaginis ovatae semen). The composition can advantageously be manufactured by fluidized bed granulation. The composition is in particular free of guar gum, is dust-free, is dispersible in water and has a pleasant taste and can be supplemented straightforwardly with vitamins, minerals, trace elements and the like.

Abstract translation: 本发明涉及一种药物组合物，其特别适合用作泻药（泻药），其中组合物组合包含药学有效量（A）番泻奈果干提取物和（B）车前草种子（plantaginis ovatae 精液）。 组合物可以有利地通过流化床造粒制备。 该组合物特别是没有瓜尔胶，无尘，可分散在水中并具有令人愉快的味道，并可直接补充维生素，矿物质，微量元素等。

公开(公告)号：US20090137496A1

公开(公告)日：2009-05-28

申请号：US11883697

申请日：2006-02-03

Applicant: Peter Heger ,  Reinhard Rettenberger ,  Carl-Friedrich Spaich

Inventor： Peter Heger ,  Reinhard Rettenberger ,  Carl-Friedrich Spaich

IPC: A61K31/7034

CPC classification number: A61K31/085 ,  A61K31/7034 ,  A61K36/15 ,  A61K36/481 ,  A61K36/482 ,  A61K36/708 ,  A61K2300/00

Abstract: The invention relates to the use of a combination of active ingredients containing hydroxystilbene, selected from resveratrol and piceatannol precursors and functional derivatives thereof, in addition to the use of the stereoisomeric forms of said ingredients, in the form of salts or phenol respectively, for producing an agent for the prevention and/or treatment of osteoporosis.

Abstract translation: 本发明涉及除了分别以盐或苯酚的形式使用所述成分的立体异构形式之外，还分别含有选自白藜芦醇和云杉醇前体及其功能衍生物的羟基二苯乙烯的活性成分的组合用于生产 用于预防和/或治疗骨质疏松症的药剂。

公开(公告)号：US20090042817A1

公开(公告)日：2009-02-12

申请号：US11883685

申请日：2006-02-03

Applicant: Peter Heger ,  Reinhard Rettenberger ,  Carl-Friedrich Spaich

Inventor： Peter Heger ,  Reinhard Rettenberger ,  Carl-Friedrich Spaich

IPC: A61K31/05 ,  A61P25/24 ,  A61P25/22 ,  A61P25/06 ,  A61P29/00 ,  A61K31/7034

CPC classification number: A61K36/708 ,  A23L33/105 ,  A61K9/2054 ,  A61K9/2846 ,  A61K9/2866 ,  A61K31/085 ,  A61K31/7034 ,  A61K36/15 ,  A61K36/481 ,  A61K36/482 ,  A61K2300/00

Abstract: The invention relates to the use of a combination of active ingredients, selected from resveratrol and piceatannol precursors and functional derivatives thereof, in addition to the use of the stereoisomeric forms of said ingredients, in the form of salts or phenol respectively, for producing an agent for the prevention and/or treatment of diseases, whose occurrence and/or progress is associated with an increased IL-6 serum level and/or whose occurrence and/or progress can be treated by a dose of a selective oestrogen receptor β (ER-β) agonist.

Abstract translation: 本发明涉及除了分别以盐或酚的形式使用所述成分的立体异构体形式之外，还可以使用选自白藜芦醇和云杉醇前体的活性成分及其功能衍生物的组合，用于生产药剂 用于预防和/或治疗其发生和/或进展与增加的IL-6血清水平相关的疾病和/或其发生和/或进展可以通过剂量的选择性雌激素受体β（ER- β）激动剂。